36 results
8-K
EX-10.1
BFRI
Biofrontera Inc
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions
8-K
EX-99.1
BFRI
Biofrontera Inc
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use
5:25pm
and pain during illumination that was managed by a cooling air stream.
About Actinic Keratosis
Actinic keratosis (AK) is the most common pre-cancerous skin
8-K
EX-10.1
BFRI
Biofrontera Inc
3 Jan 24
Entry into a Material Definitive Agreement
5:27pm
by air courier, regular mail or any other method in accordance with New York law, with a copy to current counsel for all of the Parties (such copy shall … be served by air courier, regular mail or any other method in accordance with New York law, with a copy to cur- rent counsel for all of the Parties
8-K
EX-10.1
9a4sz58 d1er860w8o5h
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-10.2
cc2bha0eo0me41vu
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-10.1
tg56ltwczoxmrbh6h
20 May 22
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
4:30pm
424B3
6065xdj7xai1xbtqgt
8 Apr 22
Prospectus supplement
9:47pm
424B3
sd1lbkhbz
8 Apr 22
Prospectus supplement
9:45pm
10-K
8qb6f5e55
8 Apr 22
Annual report
9:14pm
424B3
5ekb5lv
23 Dec 21
Prospectus supplement
5:18pm
DRS
vmn91ve
14 Dec 21
Draft registration statement
12:00am
8-K
EX-10.1
izgs6l1k sexbgmq0vl
3 Dec 21
Entry into a Material Definitive Agreement
8:43am
8-K
EX-1.1
022utzx3lwtkft
3 Nov 21
Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering
8:55am
424B4
ak3czdbn dhh
1 Nov 21
Prospectus supplement with pricing info
4:59pm